» Articles » PMID: 33637564

The Common Germline Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model

Abstract

The TP53-R337H founder mutation exists at a high frequency throughout southern Brazil and represents one of the most common germline TP53 mutations reported to date. It was identified in pediatric adrenocortical tumors in families with a low incidence of cancer. The R337H mutation has since been found in association with early-onset breast cancers and Li-Fraumeni syndrome (LFS). To study this variability in tumor susceptibility, we generated a knockin mutant p53 mouse model (R334H). Endogenous murine p53-R334H protein was naturally expressed at high levels in multiple tissues and was functionally compromised in a tissue- and stress-specific manner. Mutant p53-R334H mice developed tumors with long latency and incomplete penetrance, consistent with many human carriers being at a low but elevated risk for cancer. These findings suggest the involvement of additional cooperating genetic alterations when TP53-R337H occurs in the context of LFS, which has important implications for genetic counseling and long-term clinical follow-up. SIGNIFICANCE: A p53-R334H knockin mouse serves as an important model for studying the most common inherited germline TP53 mutation (R337H) that is associated with variable tumor susceptibility.

Citing Articles

Personalized screening strategies for R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriers.

Galante P, Guardia G, Pisani J, Sandoval R, Barros-Filho M, Gifoni A Lancet Reg Health Am. 2025; 42:100982.

PMID: 39895904 PMC: 11787607. DOI: 10.1016/j.lana.2024.100982.


AI-guided identification of risk variants for adrenocortical tumours in p.R337H carrier children: a genetic association study.

Figueiredo B, Dupont F, Portelli G, Costa T, Custodio G, Paraizo M Lancet Reg Health Am. 2024; 38:100863.

PMID: 39258234 PMC: 11386259. DOI: 10.1016/j.lana.2024.100863.


LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline Mutations.

Nguyen N, Dodd-Eaton E, Peng G, Corredor J, Jiao W, Woodman-Ross J JCO Clin Cancer Inform. 2024; 8:e2300167.

PMID: 38346271 PMC: 10871774. DOI: 10.1200/CCI.23.00167.


Association of germline variants with somatic variants in breast tumors in a genome-wide study.

Tjader N, Beer A, Ramroop J, Tai M, Ping J, Gandhi T medRxiv. 2023; .

PMID: 38106140 PMC: 10723566. DOI: 10.1101/2023.12.06.23299442.


How Do Cancer-Related Mutations Affect the Oligomerisation State of the p53 Tetramerisation Domain?.

Nicolini F, Todorovski T, Puig E, Diaz-Lobo M, Vilaseca M, Garcia J Curr Issues Mol Biol. 2023; 45(6):4985-5004.

PMID: 37367066 PMC: 10296842. DOI: 10.3390/cimb45060317.


References
1.
Pinto E, Billerbeck A, Villares M, Domenice S, Mendonca B, Latronico A . Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol. 2005; 48(5):647-50. DOI: 10.1590/s0004-27302004000500009. View

2.
von Massenhausen A, Tonnus W, Linkermann A . Cell Death Pathways Drive Necroinflammation during Acute Kidney Injury. Nephron. 2018; 140(2):144-147. DOI: 10.1159/000490807. View

3.
Sah V, Attardi L, Mulligan G, Williams B, Bronson R, Jacks T . A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 1995; 10(2):175-80. DOI: 10.1038/ng0695-175. View

4.
Zindy F, Eischen C, Randle D, Kamijo T, Cleveland J, Sherr C . Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998; 12(15):2424-33. PMC: 317045. DOI: 10.1101/gad.12.15.2424. View

5.
Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View